5 Truths About Oncology Pathways You Need to Know Today! Go "Behind the Scenes" to Learn How Pathways Are Created

Madison, NJ, November 06, 2013 --(PR.com)-- Pathways are the new oncology formulary, and their influence is increasingly significant whether you are in clinical development, launch, or growth mode for your product. It is more important than ever for oncology manufacturers to take advantage of opportunities to bolster product position within pathways, and to ensure pipeline success. Over the past two years, Reimbursement Intelligence has conducted extensive research to understand pathway trends and their impact on the pharmaceutical industry. The company’s most recent report, 2013 Pathways Tracker, helps to clarify some of the missteps the industry has taken when attempting to build strategic planning and engagement for commercial and pipeline oncology products.

When creating pathways, pathway designers are relying on input from oncologists far more frequently than that from pathway vendors or payers, according to Reimbursement Intelligence’s 2013 Pathways Tracker. But many manufacturers have not adjusted their strategy accordingly, and may be spending too much time pursuing pathway vendors who are less involved in pathway development than originally thought. According to Dr. John Whang, COO of Reimbursement Intelligence, “Our goal is to help oncology manufacturers understand that the efforts to engage pathway decision-makers need to be appropriately balanced. It is not in a company’s best interest to over-invest in a group of people who ultimately do not make the final pathway decision for a given oncology practice.”

Reimbursement Intelligence is now conducting a free webinar to give oncology manufacturers the facts on how pathways are developed, including who is really creating them and why. John Hennessy, VP of Operations at Sarah Cannon, will be the guest speaker, and will answer questions related to oncology pathways, and what they mean for manufacturers. Mr. Hennessy has extensive experience in oncology, including the evolving role of pathways, and will spend the session lending valuable perspective to oncology manufacturers, including what data is most important to pathway designation, and the best strategies for communicating an oncolytic’s value proposition to pathway decision-makers.

Please register at www.reimbursementintelligence.com. You can also contact Jessica DiPaolo at 973-805-2305 or jdipaolo@reimbursementintelligence.com